Literature DB >> 18278371

[Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital].

Ricardo Mingarini Terra1, Lisete Ribeiro Teixeira, Ricardo Beyruti, Teresa Yae Takagaki, Francisco Suso Vargas, Fabio Biscegli Jatene.   

Abstract

OBJECTIVE: To evaluate the experience in diagnosing and treating malignant pleural mesothelioma (MPM) accumulated over 5 years in a tertiary public hospital.
METHODS: The medical charts of the patients diagnosed with MPM between January of 2000 and February of 2005 were evaluated retrospectively.
RESULTS: Of the 17 patients analyzed, 14 were male and 3 were female. The mean age was 54.1 years (range, 13-75 years). The biopsy specimens for histopathological examination were obtained through thoracoscopy in 9 patients (53%), Cope needle in 5 (29.5%), and open pleural biopsy in 3 (17.5%). The following histological types were identified: epithelial, in 14 patients (82%); sarcomatoid, in 1 (6%); and biphasic, in 2 (12%). The therapeutic approaches used were as follows: multimodal (pleuropneumonectomy and adjuvant radiotherapy and chemotherapy) in 6 patients (35%); chemotherapy and radiotherapy in 6 (35%); radiotherapy alone in 3 (17.5%); and chemotherapy alone in 2 (12%). The mean survival was 11 months (range, 1-26 months).
CONCLUSIONS: In the cases studied, an integrated multidisciplinary approach was used, and a highly complex hospital infrastructure was available for the diagnosis and treatment of MPM, as recommended in the literature. However, the mean survival was only 11 months, reflecting the aggressiveness of the disease.

Entities:  

Mesh:

Year:  2008        PMID: 18278371     DOI: 10.1590/s1806-37132008000100004

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN: 1806-3713            Impact factor:   2.624


  1 in total

1.  Mesothelioma in a developing country: a retrospective analysis of the diagnostic process.

Authors:  Paulo Henrique Peitl Gregório; Ricardo Mingarini Terra; Leonardo Pontual Lima; Paulo Manuel Pêgo-Fernandes
Journal:  J Bras Pneumol       Date:  2022-08-19       Impact factor: 2.800

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.